

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Toru KONO et al. Conf.:
Appl. No.: NEW Group: UNASSIGNED
Filed: March 3, 2004 Examiner: UNASSIGNED
For: AGENT FOR PROPHYLAXIS OR TREATMENT OF
INFLAMMATORY BOWEL DISEASES

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 3, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
10/129,361

U.S. Filing Date(s)
May 3, 2002

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.


If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By

 #32,221
Raymond C. Stewart, #21,066

25
RCS/TBS/jmb
0020-5227P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s) : ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 02/12/2004)

Form PTO-1449 <div style="text-align: center;"> INFORMATION DISCLOSURE CITATION IN AN APPLICATION </div> <div style="text-align: center; font-size: small;"> (Use several sheets if necessary) </div>				ATTY. DOCKET NO. 0020-5227P		APPLICATION NO. NEW			
				APPLICANT Toru KONO et al.					
				FILING DATE March 3, 2004		GROUP UNASSIGNED			
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
FOREIGN PATENT DOCUMENTS									
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
	EP	0078152	A1	1993-05-04	EPO				
	JP	5877814	A	1983-05-11	JAPAN				
	JP	63165361	A	1988-07-08	JAPAN				
	JP	2167258	A	1990-06-27	JAPAN				
	JP	10338632	A	1998-12-22	JAPAN				
OTHER DOCUMENTS									
(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
OHKUSA et al., "Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori: A randomized controlled trial", abstract, Annals of Internal Medicine, 1998, 129(9), 712-715.									
OHKUSA et al., "Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection:, abstract, Alimentary Pharmacology and Therapeutics, 1998, 12(5), 457-461.									
YARIMIZU et al, Oncology Reports, Vol. 5, (1998), pp.1103-1107.									
EXAMINER					DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									